Extended Data Fig. 4: Comparative analysis of 2nd-gen CAR T cell products.
(a) On-chip response curves of leukaemia chips under treatment of different 2nd-gen CAR T cells at a dose of 10,000 CAR T cells. Data was collected from three independent experiments (n = 3), and each had 2 or 3 chips. Data was from CAR T cell and Mock T cell of three healthy donors (ND164, ND365, and TMP497), mean and s.e.m. (b) CD25 (left) and CD69 (right) expression on different 2nd-gen CAR T cells activated by interaction with leukaemia on-chip for 2 days. Data was collected from two independent experiments (n = 2), and each had 2 or 3 chips. One-way ANOVA followed by Kruskal-Wallis’ test, mean and s.e.m. (c) Radar mapping of cytokine secretion from leukaemia chip treated with different 2nd-gen CAR T cells for 2 days. Data was normalized to that of Mock T cell, corresponding to Supplementary Fig. 8. (d,e) ELISA measurement of IL-13, IL-10, IFN-γ, and I-309 secretion from (d) on-chip and (e) 2D co-culture conditions where different 2nd-gen CAR T cells interacted with leukaemia blasts for 2 days. Data was from CAR T cell and Mock T cell of three healthy donors (ND164, ND365, and TMP497). Two-way ANOVA followed by Tukey’s post hoc test, mean and s.e.m.
